← Back to Search

Prostaglandin Analog

Test - Bimatoprost 0.01% Ophthalmic Solution for Open-Angle Glaucoma

Phase 3
Waitlist Available
Research Sponsored by Amneal Pharmaceuticals, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 14 and 42 at 00.00 hours, 04.00 hours, and 08.00 hours.
Awards & highlights

Summary

This trial is designed to show that a generic bimatoprost solution is equivalent to the brand name product in subjects with glaucoma or ocular hypertension.

Eligible Conditions
  • Open-Angle Glaucoma
  • Ocular Hypertension

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 14 and 42 at 00.00 hours, 04.00 hours, and 08.00 hours.
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 14 and 42 at 00.00 hours, 04.00 hours, and 08.00 hours. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Mean difference in the intraocular pressure (IOP) of both eyes between the two treatment groups.
Secondary study objectives
AE Monitoring for Safety of Bimatoprost ophthalmic solution 0.01%

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Bimatoprost 0.01% Ophthalmic SolutionExperimental Treatment1 Intervention
Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Group II: LUMIGAN® 0.01% Ophthalmic SolutionActive Control1 Intervention
Pharmaceutical dosage form contains LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bimatoprost
FDA approved

Find a Location

Who is running the clinical trial?

Amneal Pharmaceuticals, LLCLead Sponsor
11 Previous Clinical Trials
27,837 Total Patients Enrolled
CBCC Global ResearchNETWORK
7 Previous Clinical Trials
1,115 Total Patients Enrolled
~53 spots leftby Sep 2025